Natera Inc. has announced the publication of a new prospective clinical trial in the journal Transplantation Direct, evaluating the use of its Prospera™ donor-derived cell-free DNA (dd-cfDNA) test for lung transplant recipients. Conducted by The Ohio State University Wexner Medical Center, the study assessed whether Prospera-guided monitoring could reduce the need for routine transbronchial biopsies after lung transplantation. Results from the clinical trial have been published and indicate that physicians omitted the 9-month biopsy in approximately 75% of patients identified as low risk by Prospera, with no significant difference in acute rejection rates, lung function, or immunologic stability compared to patients who underwent the biopsy. At one year post-transplant, about 95% of patients who skipped the 9-month biopsy did not require treatment for acute rejection. The findings suggest that Prospera-guided care may help reduce invasive procedures while maintaining patient outcomes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260126928485) on January 26, 2026, and is solely responsible for the information contained therein.